Fulcrum Therapeutics, Inc. (FULC) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 637.5% |
| FCF Growth (YoY) | 2319.0% |
| Price / Book | 0.94 |
| Price / Sales | 3.64 |
| FCF Yield | -39.7% |
| Altman Z-Score | 6.92 (safe) |
| Sector P/E (Healthcare) | 21.7 |
FULC overview · FULC earnings · FULC KPIs · FULC investor relations · FULC ownership · FULC peers · FULC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.